Li Xia, D'Souza Manoranjan S, Niño Ana M, Doherty James, Cross Alan, Markou Athina
Department of Psychiatry, M/C 0603, School of Medicine, University of California San Diego, 9500 Gilman Drive, La Jolla, CA, 92093-0603, USA.
Present address: Sage Therapeutics, Cambridge, MA, 02142, USA.
Psychopharmacology (Berl). 2016 May;233(10):1801-14. doi: 10.1007/s00213-016-4220-2. Epub 2016 Feb 13.
Numerous medication development strategies seek to decrease nicotine consumption and prevent relapse to tobacco smoking by blocking glutamate transmission. Decreasing glutamate release by activating presynaptic inhibitory metabotropic glutamate (mGlu)2/3 receptors inhibits the reinforcing effects of nicotine and blocks cue-induced reinstatement of nicotine-seeking behavior in rats. However, the relative contribution of mGlu2 receptors in nicotine dependence is still unknown.
The present study evaluated the role of mGlu2 receptors in nicotine-taking and nicotine-seeking behavior using the novel, relatively selective mGlu2 positive allosteric modulators (PAMs) AZD8418 and AZD8529.
Acute treatment with AZD8418 (0.37, 1.12, 3.73, 7.46, and 14.92 mg/kg) and AZD8529 (1.75, 5.83, 17.5, and 58.3 mg/kg) deceased nicotine self-administration and had no effect on food-maintained responding. Chronic treatment with AZD8418 attenuated nicotine self-administration, but tolerance to this effect developed quickly. The inhibition of nicotine self-administration by chronic AZD8529 administration persisted throughout the 14 days of treatment. Chronic treatment with either PAMs inhibited food self-administration. AZD8418 (acute) and AZD8529 (acute and subchronic) blocked cue-induced reinstatement of nicotine- and food-seeking behavior.
These findings indicate an important role for mGlu2 receptors in the reinforcing properties of self-administered nicotine and the motivational impact of cues that were previously associated with nicotine administration (i.e., cue-induced reinstatement of nicotine-seeking behavior). Thus, mGlu2 PAMs may be useful medications to assist people to quit tobacco smoking and prevent relapse.
众多药物研发策略试图通过阻断谷氨酸传递来减少尼古丁摄入并防止复吸吸烟。激活突触前抑制性代谢型谷氨酸(mGlu)2/3受体以减少谷氨酸释放,可抑制尼古丁的强化作用,并阻断线索诱导的大鼠尼古丁寻求行为的恢复。然而,mGlu2受体在尼古丁依赖中的相对作用仍不清楚。
本研究使用新型、相对选择性的mGlu2正变构调节剂(PAMs)AZD8418和AZD8529评估mGlu2受体在尼古丁摄取和尼古丁寻求行为中的作用。
用AZD8418(0.37、1.12、3.73、7.46和14.92mg/kg)和AZD8529(1.75、5.83、17.5和58.3mg/kg)进行急性治疗可减少尼古丁自我给药,且对食物维持反应无影响。用AZD8418进行慢性治疗可减弱尼古丁自我给药,但对此效应的耐受性迅速产生。在整个14天的治疗过程中,慢性给予AZD8529对尼古丁自我给药的抑制作用持续存在。用任何一种PAMs进行慢性治疗均抑制食物自我给药。AZD8418(急性)和AZD8529(急性和亚慢性)阻断线索诱导的尼古丁和食物寻求行为的恢复。
这些发现表明mGlu2受体在自我给药尼古丁的强化特性以及先前与尼古丁给药相关的线索的动机影响(即线索诱导的尼古丁寻求行为的恢复)中起重要作用。因此,mGlu2 PAMs可能是有助于人们戒烟和防止复吸的有用药物。